Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Metastatic colorectal cancer (mCRC) presents significant long-term survival challenges despite therapeutic advances.
• Standard first- and second-line treatments often leave patients with a need for further effective options to prolong life and manage symptoms.
• Selecting optimal third- and fourth-line therapies, including novel oral agents and treatment rechallenges, remains a critical clinical challenge.

Purpose of the Study:

• To highlight the importance of identifying molecular subtypes in mCRC for guiding personalized therapy.
• To review current and emerging treatment strategies for advanced mCRC, including later lines of therapy.
• To emphasize the growing focus on immunotherapy and precision medicine for mCRC, including rare molecular subtypes.

Main Methods:

• Review of current treatment paradigms for metastatic colorectal cancer.
• Discussion of emerging therapeutic agents such as TAS-102 and regorafenib.
• Exploration of treatment rechallenge strategies and novel combination therapies.
• Examination of advancements in immunotherapy and precision medicine for specific molecular subtypes.

Main Results:

• Identification of molecular subtypes is crucial for tailoring mCRC treatment pathways.
• Novel oral agents (TAS-102, regorafenib) and rechallenge strategies offer options for later-line treatment.
• Immunotherapy shows promise in mismatch repair deficient (dMMR) mCRC, driving research into enhancing immunogenicity.
• Rare molecular subtypes (e.g., HER2-positive, NTRK fusions) are emerging targets for precision agents.

Conclusions:

• Continued research into molecular subtypes and novel agents is essential for improving outcomes in mCRC.
• Precision medicine and immunomodulatory strategies hold significant promise for future mCRC treatment.
• Clinical trials exploring these avenues are vital for translating research findings into routine patient care.